Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.32 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357872 | 0.92 | ALK (0.51) | ALKJAK2RORC | |
| SCHEMBL13633105 | 0.92 | ALK (0.43) | ALKJAK2PTK2PTK2BRORC | |
| SCHEMBL13633020 | 0.90 | ALK (0.41) | ALKJAK2PTK2PTK2BRORC | |
| Trifluoroacetic Acid SCHEMBL4361818 | 0.88 | ALK (0.47) | ALKJAK2PTK2PTK2BRORC | |
| SCHEMBL13633104 | 0.88 | ALK (0.43) | ALKJAK2PTK2PTK2B | |
| SCHEMBL13633993 | 0.88 | ALK (0.41) | ALKJAK2PTK2PTK2BL3MBTL1 | |
| SCHEMBL13632985 | 0.88 | ALK (0.44) | ALKJAK2PTK2PTK2B | |
| SCHEMBL13634050 | 0.87 | ALK (0.41) | ALKJAK2RORCSMN1; SMN2 | |
| SCHEMBL13633024 | 0.87 | ALK (0.41) | ALKJAK2PTK2PTK2BL3MBTL1 | |
| SCHEMBL13633112 | 0.87 | ALK (0.40) | ALKJAK2RORCL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885JAK2 1/4885HTR1A 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.